Rajagopal Ramesh

Contact Information:
Rajagopal Ramesh


Ramesh, Rajagopal (HSC)

Department of:

College Of Medicine/Pathology -Professor

Center of:

Peggy & Charles Stephenson Oklahoma Cancer Center -Jim & Christy Everest Endowed Chair in Cancer Developmental Therapeutics

Other Organization:

Department of Pharmaceutical Sciences -Adjunct Professor


Osmania University, Hyderabad, India   B.Sc. - Biology   1985
Osmania University, Hyderabad, India   M.Sc. - Microbiology   1967
Annamalai University, Tamil Nadu, India   DBA   1992
All India Institute of Medical Sciences, New Delhi, India   Ph.D. - Molecular Biology   1994

Professional Interest/Expertise/Specializations:
Studies in my laboratory are mainly focused on novel gene-based therapeutics using viral and non-viral vectors with emphasis on translational cancer research. There are two major research areas that are actively being pursued in the laboratory. The first research area is the development and testing of non-viral and nanoparticle-based gene delivery for cancer treatment, and the second research area is studying the antitumor and anti-angiogenic properties of IL-24. Our findings have lead to Phase I clinical trials for treatment of solid tumors.


Research Projects:

Selected Publications:

EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells.
2011    Yokoyama T, Tam J, Kuroda S, Scott AW, Aaron J, Larson T, Correa AM, Shanker M, Kondo S, Roth JA, Sokolov K, Ramesh R.
PLoS ONE 6 (11): 1-13, e25507, 2011. [doi:10.1371/journal.pone.0025507]
Selective targeting of antibody conjugated multifunctional nanoclusters (nanoroses) to epidermal growth factor receptors in cancer cells.
2011    Ma LL, Tam JO, Willsey BW, Rigdon D, Ramesh R, Sokolov K, Johnston KP
Tumor suppressor gene-based nanotherapy: from test tube to the clinic.
2011    Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth J A , Ramesh R.
J Drug Delivery; 1-10; doi:10.1155/2011/465845. (Online-only journal)
A peptidogylcan monomer with the glutamine to serine change and basic peptides bind in silico to TLR-2 (403-455).
2011    Li Y, Efferson CL, Ramesh R, Peoples GE, Hwu P, Ioannides CG.
Cancer Immunol Immunother;60(4):515-524.
Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.
2011    Mandal P, Gao F, Lu Z, Ramesh R, Sanderson Birtwistle J, Ren Z, Chen X, Kaluarachichi K, Ekmekcioglu S, Bast RC, Liao WS, McMurray JS.
J Med Chem:54(10):3549-63.
Keywords, Tags: